作者
Michael McDonald, Sean Virani, Michael Chan, Anique Ducharme, Justin A Ezekowitz, Nadia Giannetti, George A Heckman, Jonathan G Howlett, Sheri L Koshman, Serge Lepage, Lisa Mielniczuk, Gordon W Moe, Eileen O’meara, Elizabeth Swiggum, Mustafa Toma, Shelley Zieroth, Kim Anderson, Sharon A Bray, Brian Clarke, Alain Cohen-Solal, Michel D’astous, Margot Davis, Sabe De, Andrew DM Grant, Adam Grzeslo, Jodi Heshka, Sabina Keen, Simon Kouz, Douglas Lee, Frederick A Masoudi, Robert McKelvie, Marie-Claude Parent, Stephanie Poon, Miroslaw Rajda, Abhinav Sharma, Kyla Siatecki, Kate Storm, Bruce Sussex, Harriette Van Spall, Amelia Ming Ching Yip
发表日期
2021/4/1
来源
Canadian Journal of Cardiology
卷号
37
期号
4
页码范围
531-546
出版商
Elsevier
简介
In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we provide comprehensive recommendations and practical tips for the pharmacologic management of patients with HF with reduced ejection fraction (HFrEF). Since the 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of HF, substantial new evidence has emerged that has informed the care of these patients. In particular, we focus on the role of novel pharmacologic therapies for HFrEF including angiotensin receptor-neprilysin inhibitors, sinus node inhibitors, sodium glucose transport 2 inhibitors, and soluble guanylate cyclase stimulators in conjunction with other long established HFrEF therapies. Updated recommendations are also provided in the context of the clinical setting for which each of these agents might be prescribed; the potential value of each therapy is reviewed …
学术搜索中的文章
M McDonald, S Virani, M Chan, A Ducharme… - Canadian Journal of Cardiology, 2021
